CONCLUSION
ESCC
In summary, our prospective study demonstrated the efficacy of irinotecan combined with raltitrexed for salvage chemotherapy of advanced ESCC prior to irinotecan monotherapy, and there is no increase in side effects. The PFS and OS of irinotecan + raltitrexed may be better than that of irinotecan monotherapy, especially in second‐line treatment, which should be confirmed with a phase III study including much more patients.